EXTH-58. Effects of TORC1/2 Inhibitor MLN0128 Alone and in Combination with MEK Inhibition in BRAF-mutated Glioma Models in Vitro and In Vivo

Published in
Liu, Kevin X., Sabine Mueller, Rogier Dik, Xiaodong Yang, Steven DuBois, Angela J. Waanders, Adam C. Resnick, William A. Weiss, and Daphne Haas-Kogan



MLN0128, a second-generation ATP-competitive pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2. We investigated the effects of MLN0128 monotherapy and in combination with MEK and BRAFV600E inhibition in models of pediatric low-grade glioma (PLGG).


We used human glioma cell lines expressing BRAFV600E (AM38), wild-type BRAF (LN229, TN98, SF188) and isogenic systems of KIAA1549:BRAF-expressing NIH3T3 cells. Signaling inhibitors included MLN0128, everolimus, BRAFV600E specific inhibitor PLX4720, and MEK specific inhibitors AZD6244 and GSK1120212. Cell proliferation was determined using an ATP-based assay. Biochemical effects were assessed using western blot analysis. The DBTRG (BRAFV600E) xenograft mouse model was used to assess in vivo efficacy.


MLN0128 monotherapy demonstrates more potent anti-proliferative effects compared to everolimus in all tested PLGG lines independent of BRAF status. As expected, treatment with MLN0128 leads to down-regulation of p-AKT, p-S6 and p-4EBP1, whereas treatment with everolimus only reduces expression of p-S6. MEK inhibition with AZD6244 effectively decreases p-ERK expression in all lines; however, the addition of MLN0128 to AZD6244 causes a rebound in p-ERK expression in BRAFWT gliomas but not in gliomas expression BRAFV600E or KIAA1549:BRAF alterations. In cells carrying either the BRAFV600Eor KIAA1549:BRAF alteration, combined treatment with MLN0128 and GSK1120212 or AZD6244 leads to synergistic anti-proliferative effects but such synergy is not evident in BRAFWT gliomas. In vivo studies show superior efficacy of combinations of PLX4720 and MLN0128 compared to monotherapies (p<0.02) or combination of PLX4720 + everolimus (p=0.03).


MLN0128 displays synergistic anti-neoplastic effects with MEK inhibition in gliomas bearing BRAFV600Eor KIAA1549:BRAF. In BRAF wild-type cells, such synergy is not present, potentially due to rebound in p-ERK when MLN0128 is combined with AZD6244. Combination therapy with MLN0128 + PLX4720 prolongs survival in a BRAFV600E mutant glioma model and is superior to monotherapy or everolimus + PLX4720 combination.